Recombinant full length protein corresponding to Human Bcl-XL. Database link: Q07817
Abcam is committed to meeting high standards of ethical manufacturing and as such, we will be discontinuing this product, which has been generated by the ascites method, within the next year. We are sorry for any inconvenience this may cause. If you would like help finding an alternative product, please do not hesitate to contact our scientific support team.
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
Use 3µg for 106 cells. ab18436-Mouse monoclonal IgG3, is suitable for use as an isotype control with this antibody.
Use at an assay dependent concentration. Predicted molecular weight: 26 kDa.
Potent inhibitor of cell death. Inhibits activation of caspases (By similarity). Appears to regulate cell death by blocking the voltage-dependent anion channnel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Isoform Bcl-X(S) promotes apoptosis.
Bcl-X(S) is expressed at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. In contrast, Bcl-X(L) is found in tissues containing long-lived postmitotic cells, such as adult brain.
Belongs to the Bcl-2 family.
The BH4 motif is required for anti-apoptotic activity. The BH1 and BH2 motifs are required for both heterodimerization with other Bcl-2 family members and for repression of cell death.
Proteolytically cleaved by caspases during apoptosis. The cleaved protein, lacking the BH4 motif, has pro-apoptotic activity.
Mitochondrion membrane. Nucleus membrane. Mitochondrial membranes and perinuclear envelope.
References for Anti-Bcl-XL antibody [7B2.5] (Biotin) (ab25062)
This product has been referenced in:
Phillips DC et al. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J5:e368 (2015).
Read more (PubMed: 26565405) »